MarketPeel
Insider Trading Intelligence
Pricing
…
PB

Peter Blume-jensen

ACRV
PRESIDENT AND CEO · ACRIVON THERAPEUTICS, INC. · CIK 0001950499
FILING MIX · LIFETIME39%/61%
BUYS
17
SELLS
27
TOTAL VALUE
$4.53M
COMPANIES
1
ACTIVE SINCE
Nov 2022
HOLDINGS NOW
2,245,317
AVG SELL PX
$4.88
TRADE KIND
SHOWING 44 / 44
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Peter Blume-jensen, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+14.21%-0.72%+14.93%+14.93%—
14d1+100.00%+3.28%+0.73%+2.55%+2.55%—
30d1+0.00%-10.93%-1.25%-9.68%-9.68%—
60d1+0.00%-7.10%-3.09%-4.01%-4.01%—
90d1+0.00%-10.38%+0.59%-10.98%-10.98%—
180d1(1 pending)——————
1y1(1 pending)——————
2y1(1 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ACRV · 2,245,317 shares · as of May 21, 2026
0724,4241,448,8482,173,2722,897,6962023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 17 buys / 27 sellsCOVERAGE · 15 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
13,729$1.79$24.6K2,245,317May 21, 2026May 26, 2026 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
72,706——386,343May 18, 2026May 20, 2026 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
180,095——2,259,046May 18, 2026May 20, 2026 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
1,253$1.92$2.4K2,078,951May 14, 2026May 18, 2026 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
490$1.92$941313,637May 14, 2026May 18, 2026 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
417,210——417,210Mar 1, 2026Mar 3, 2026 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
185,495——185,495Mar 1, 2026Mar 3, 2026 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
14,265$1.53$21.8K2,080,204Feb 21, 2026Feb 24, 2026 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
1,302$1.63$2.1K2,094,469Feb 14, 2026Feb 18, 2026 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
579$1.63$944314,127Feb 14, 2026Feb 18, 2026 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASE
President and CEO
49,000$1.68$82.1K2,095,771Jan 14, 2026Jan 16, 2026 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
19,904$2.30$45.8K2,046,771Nov 21, 2025Nov 25, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
490$2.24$1.1K314,706Nov 14, 2025Nov 18, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
59,765$2.24$133.9K2,066,675Nov 14, 2025Nov 18, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
19,905$1.32$26.3K2,126,440Aug 21, 2025Aug 25, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
490$1.39$681315,196Aug 14, 2025Aug 18, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
59,766$1.39$83.1K2,146,345Aug 14, 2025Aug 18, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
19,904$1.15$22.9K2,206,111May 21, 2025May 23, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
59,766$1.14$68.1K2,226,015May 14, 2025May 16, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
491$1.14$560315,686May 14, 2025May 16, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
390,390——390,390Mar 1, 2025Mar 4, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
140,540——140,540Mar 1, 2025Mar 4, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
19,904$5.54$110.3K2,285,781Feb 21, 2025Feb 25, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
579$5.42$3.1K316,177Feb 14, 2025Feb 19, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
37,152$5.42$201.4K2,305,685Feb 14, 2025Feb 19, 2025 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
19,910$6.44$128.2K2,342,837Nov 21, 2024Nov 25, 2024 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
59,766$7.92$473.3K2,362,747Nov 14, 2024Nov 18, 2024 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
490$7.92$3.9K316,756Nov 14, 2024Nov 18, 2024 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
79,616$9.19$731.7K2,422,513Aug 21, 2024Aug 23, 2024 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
59,765$7.02$419.6K2,502,129Aug 14, 2024Aug 16, 2024 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
54,918$8.36$459.1K2,561,894May 14, 2024May 16, 2024 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
225,226——225,226Mar 1, 2024Nov 27, 2024 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
90,090——90,090Mar 1, 2024Nov 27, 2024 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
41,861$3.40$142.3K2,616,812Feb 14, 2024Feb 16, 2024 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
239,023$5.08$1.21M2,658,673Nov 14, 2023Nov 16, 2023 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
493,994——2,897,696Aug 21, 2023Aug 23, 2023 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
President and CEO
33,605——90,855May 31, 2023Jun 1, 2023 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASE
President and CEO
33,605$3.88$130.4K2,403,702May 31, 2023Jun 1, 2023 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
26,707——320,705Nov 14, 2022Nov 16, 2022 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
934,731——1,806,588Nov 14, 2022Nov 16, 2022 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
80,120——80,120Nov 14, 2022Nov 16, 2022 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
180,269——180,269Nov 14, 2022Nov 16, 2022 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
60,090——2,370,097Nov 14, 2022Nov 16, 2022 ↗View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
503,419——2,310,007Nov 14, 2022Nov 16, 2022 ↗View →
Other insiders · ACRV
Loading peer insiders…
About this filer
CIK 0001950499
ROLE
President and CEO
PRIMARY
ACRV
COMPANIES
1
ACTIVE SINCE
Nov 2022
MARKETPEEL · /INSIDER/0001950499DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback